Epzicom

Indications for Use

Epzicom is used to treat HIV-1 infection in adults and pediatric patients who weigh at least 25 kg (approximately 55 pounds). It is a combination of two active ingredients, abacavir and lamivudine, which belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

This medication is not a standalone treatment. It must be used in combination with other antiretroviral medicines to effectively manage the virus.

Goals of Treatment

When used as part of a complete HIV treatment regimen, Epzicom is intended to:

• Reduce the viral load (the amount of HIV in the blood) to levels that are as low as possible.
• Increase the number of CD4+ (T) cells, which are white blood cells that help the immune system fight off infections.

By controlling the virus, the medication helps improve the immune system's function and may reduce the risk of developing illnesses associated with HIV infection.

Important Considerations

Epzicom is not a cure for HIV-1 infection or AIDS. It is a long-term management tool that helps keep the virus under control. Before starting treatment, healthcare providers require a specific blood test to check for the HLA-B*5701 genetic marker, as this medication is only appropriate for patients who test negative for this marker.

Mechanism of Action

Epzicom contains two active ingredients: abacavir and lamivudine. Both of these medications belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

To understand how Epzicom works, it is helpful to know how HIV spreads in the body:

• Blocking Replication: HIV uses an enzyme called reverse transcriptase to convert its genetic material (RNA) into DNA. This step is necessary for the virus to make copies of itself and infect new cells.
• Chain Termination: Abacavir and lamivudine mimic the natural building blocks that the virus uses to create its DNA. When the virus tries to use these medications instead of the real building blocks, the DNA chain is broken, and the replication process stops.

By preventing the virus from multiplying, Epzicom helps reduce the total amount of HIV in the blood, often referred to as the viral load. While this medication does not cure HIV, lowering the viral load allows the immune system to function better and increases the count of CD4 cells, which are white blood cells that help the body fight infections.

Common Side Effects

Many people taking Epzicom experience mild to moderate side effects. These may include:

• Trouble sleeping (insomnia)
• Headache or dizziness
• Nausea, vomiting, or diarrhea
• Tiredness or lack of energy
• Fever or chills
• Loss of appetite
• Rash
• Depression or anxiety

Serious Side Effects

Some side effects can be severe and require immediate medical care. Contact a healthcare provider right away if you experience symptoms of the following:

• Hypersensitivity Reaction: This is a serious allergic reaction that often involves symptoms in two or more of the following groups: fever, rash, gastrointestinal issues (nausea, vomiting, diarrhea, stomach pain), general ill feeling (fatigue, body aches), or respiratory issues (sore throat, cough, shortness of breath).
• Lactic Acidosis: A buildup of acid in the blood that can cause unusual muscle pain, stomach pain with nausea and vomiting, coldness in the arms and legs, or feeling very weak and tired.
• Liver Problems: Symptoms may include yellowing of the skin or eyes (jaundice), dark-colored urine, light-colored stools, or pain on the right side of the stomach area.
• Immune System Changes: The immune system may become more active and attack old or hidden infections, a condition known as immune reconstitution syndrome.
• Worsening of Hepatitis B: If you have Hepatitis B, the infection may become much worse if you stop taking this medication without medical supervision.

Hypersensitivity Reactions

Epzicom contains abacavir, which can cause serious and sometimes fatal allergic reactions. Before starting treatment, a genetic test for the HLA-B*5701 allele is required. Individuals who test positive for this genetic marker are at a higher risk for a hypersensitivity reaction and must not take this medication. Symptoms of a reaction often include fever, rash, nausea, vomiting, diarrhea, abdominal pain, fatigue, or respiratory issues like sore throat and cough. If a reaction is suspected, the medication must be stopped immediately and never restarted.

Hepatitis B Virus Exacerbation

Testing for chronic hepatitis B virus (HBV) infection is recommended before starting Epzicom. In patients with both HIV-1 and HBV, stopping the medication can lead to severe, acute flare-ups of hepatitis B. Liver function should be monitored closely for several months in patients who discontinue treatment.

Lactic Acidosis and Liver Problems

There is a risk of lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty deposits (steatosis). These conditions can be life-threatening. Treatment may need to be paused if clinical or laboratory findings suggest liver toxicity or lactic acidosis.

Immune Reconstitution Syndrome

As the immune system strengthens during treatment, it may respond intensely to previously hidden or inactive infections, such as pneumonia, herpes, or tuberculosis. This inflammatory response can occur shortly after starting antiretroviral therapy and may require further medical evaluation.

Heart Health

Some observational studies have suggested a possible increased risk of heart attack (myocardial infarction) in people taking abacavir. This risk should be considered, especially for individuals with existing cardiovascular risk factors like high blood pressure, diabetes, or smoking.

Contraindications

Epzicom is not recommended for individuals with moderate to severe liver impairment. It is also contraindicated for anyone with a known allergy to abacavir, lamivudine, or any other ingredients in the medication.

Pregnancy

There are no adequate and well-controlled studies of Epzicom in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Healthcare providers are encouraged to register patients in the Antiretroviral Pregnancy Registry, which monitors outcomes in people who take HIV medications during pregnancy.

Available data from the registry have not shown a significant increase in the risk of major birth defects for abacavir or lamivudine when compared to the background rate in the general population. However, because animal studies have shown some potential for harm at high doses, clinical caution is maintained.

Breastfeeding

The Centers for Disease Control and Prevention (CDC) recommends that mothers infected with HIV-1 not breastfeed their infants to avoid the risk of transmitting the virus after birth. Additionally, both abacavir and lamivudine are known to pass into human breast milk.

Because of the potential for HIV-1 transmission and the risk of adverse reactions in the infant, breastfeeding is not recommended while taking Epzicom.

Dosage Forms

Epzicom is available as a film-coated tablet for oral administration. This medication is a fixed-dose combination that contains two active ingredients in a single pill:

• Abacavir
• Lamivudine

The tablets are capsule-shaped and are designed to be taken by mouth.

FDA Approval and Indications

Epzicom, a combination of abacavir and lamivudine, was approved by the U.S. Food and Drug Administration (FDA) in August 2004. It is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg, when used in combination with other antiretroviral agents.

Boxed Warnings

The FDA has issued several boxed warnings for Epzicom due to the risk of serious side effects:

• Hypersensitivity Reactions: Serious and sometimes fatal allergic reactions can occur with the abacavir component. Patients must be screened for the HLA-B*5701 allele before starting treatment. Those who test positive for this genetic marker should not take Epzicom.
• Lactic Acidosis and Severe Hepatomegaly: There is a risk of lactic acidosis (buildup of acid in the blood) and severe liver enlargement with fatty liver, which can be fatal.
• Hepatitis B Exacerbations: In patients co-infected with HIV-1 and the hepatitis B virus (HBV), stopping treatment with lamivudine-containing products like Epzicom has been associated with severe acute flare-ups of hepatitis B. Liver function should be closely monitored in these patients if the drug is discontinued.

Regulatory Requirements

Because of the risk of hypersensitivity reactions, the FDA requires a Medication Guide to be provided to every patient receiving Epzicom. Healthcare providers are also instructed to provide patients with a Warning Card that summarizes the symptoms of an allergic reaction, which the patient should carry with them at all times.

Brand vs. Generic Costs

Epzicom is available as a brand-name medication and as a generic version containing abacavir and lamivudine. Generic medications contain the same active ingredients as the brand-name version but are usually available at a significantly lower price.

Insurance and Pharmacy Variables

The amount you pay out-of-pocket is often determined by your insurance provider's drug list, or formulary. Many insurance plans place generic drugs in a lower cost-sharing tier than brand-name drugs. Additionally, prices may differ between local retail pharmacies and mail-order pharmacy services.

Assistance Programs

Financial assistance may be available for eligible patients through various channels:

• Patient Assistance Programs: Some pharmaceutical companies and non-profit organizations offer programs to help individuals who cannot afford their HIV medications.
• Copay Savings Cards: Manufacturers may offer savings cards for brand-name Epzicom to help reduce the cost for patients with private insurance.